MMP9 and idiopathic pulmonary fibrosis: When targeting MMP9, the anti-fibrotic effect is related to the reduction of TGF-β activation in a subgroup of IPF patients, which reveals an association with expression of type 1 IFN in ABC-like cells (Espindola et al., 2021).